Preeclampsia Risk in Pregnancy With Type 1 Diabetes

Share this content:
Researchers assessed whether elevated FABP4 in early pregnancy could predict preeclampsia.
Researchers assessed whether elevated FABP4 in early pregnancy could predict preeclampsia.

HealthDay News -- For women with type 1 diabetes, elevated fatty acid binding protein 4 (FABP4) in early pregnancy and in the second trimester is associated with subsequent preeclampsia, according to a study published online September 14 in Diabetes Care.

Amy C. Wotherspoon, from Queen's University in Belfast, UK, and colleagues measured serum FABP4 in 710 women from the Diabetes and Pre-eclampsia Intervention Trial in early pregnancy (median 14 weeks of gestation) and in the second trimester (median 26 weeks of gestation).

The researchers found that in women in whom preeclampsia later developed, FABP4 was significantly elevated in early pregnancy and the second trimester (both P <.001). There was an independent association for elevated second-trimester FABP4 level with preeclampsia (odds ratio, 2.87; P =.03). At both time points, the addition of FABP4 to established risk factors significantly improved net reclassification improvement, and integrated discrimination improvement in the second trimester.

"Increased second-trimester FABP4 independently predicted preeclampsia and significantly improved reclassification and discrimination," the authors write. "FABP4 shows potential as a novel biomarker for preeclampsia prediction in women with type 1 diabetes."

Reference

  1. Wotherspoon AC, Young IS, McCance DR, et al, for the Diabetes and Pre-Eclampsia Intervention Trial (DAPIT) STudy Group. Serum fatty acid binding protein 4 (FABP4) predicts pre-eclampsia in women with type 1 diabetes. Diabetes Care. 2016; doi: 10.2337/dc16-0803
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters



CME Focus